A detailed history of Raymond James & Associates transactions in Chimerix Inc stock. As of the latest transaction made, Raymond James & Associates holds 13,200 shares of CMRX stock, worth $11,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,200
Previous 23,200 43.1%
Holding current value
$11,616
Previous $20,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$0.77 - $1.07 $7,700 - $10,700
-10,000 Reduced 43.1%
13,200 $12,000
Q2 2024

Jul 19, 2024

SELL
$0.87 - $1.05 $17,400 - $21,000
-20,000 Reduced 46.3%
23,200 $20,000
Q4 2023

Jan 16, 2024

SELL
$0.9 - $1.06 $5,400 - $6,360
-6,000 Reduced 12.2%
43,200 $41,000
Q3 2023

Oct 24, 2023

SELL
$0.94 - $1.23 $9,400 - $12,300
-10,000 Reduced 16.89%
49,200 $47,000
Q2 2023

Jul 25, 2023

SELL
$1.1 - $1.54 $5,500 - $7,700
-5,000 Reduced 7.79%
59,200 $71,000
Q1 2023

Apr 14, 2023

BUY
$1.19 - $2.09 $21,590 - $37,918
18,143 Added 39.39%
64,200 $80,000
Q4 2022

Feb 08, 2023

BUY
$1.67 - $2.35 $76,915 - $108,233
46,057 New
46,057 $85,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $77.1M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.